WASHINGTON Thu Jul 31, 2014 1:45pm EDT0 Comments Tweet Share this EmailPrint Related Topics Health »
WASHINGTON (Reuters) - The U.S. Food and Drug Administration said on Thursday it has approved Boehringer Ingelheim's drug to treat chronic obstructive pulmonary disease (COPD), an umbrella term that includes chronic bronchitis and emphysema.
The drug, Striverdi Respimat, known also as olodaterol, is one of a class of drugs known as long-acting beta-adrenergic agonists (LABAs) that relax airways in the lungs to ease wheezing, cough and shortness of breath.
The drug will carry a boxed warning that LABAs can increase the risk of asthma-related death. The drug is not approved to treat asthma. COPD, which is usually caused by smoking, is the third leading cause of death in the United States.
(Reporting by Toni Clarke; Editing by Bill Trott)FILED UNDER: Health Tweet this Link this Share this Digg this EmailPrintReprints We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/Comments (0)Be the first to comment on reuters.com. Add yours using the box above.
View the Original article